Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bempedoic acid + obicetrapib
- Development stage
- Unknown
- Lead developer
- Esperion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
bempedoic acid + obicetrapib is a combination of two oral lipid-lowering agents with distinct mechanisms of action. Bempedoic acid is an ATP-citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver, while obicetrapib is an investigational, potent cholesteryl ester transfer protein (CETP) inhibitor that lowers LDL-C and increases HDL-C. This combination is primarily recognized in the context of a Phase 3 comparative clinical trial (NCT06041503) sponsored by A. Menarini International Licensing, which evaluates the relative efficacy and safety of the two drugs as separate treatments in patients with dyslipidemia or hypercholesterolemia at high cardiovascular risk. As of now, there is no established fixed-dose combination of these two specific agents.
- Other names
- obicetrapib + bempedoic acid
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)CETPSLCO1B3 (Organic anion transporting polypeptide 1B3)OAT2 (Solute carrier family 22 member 7)SLC22A8 (Organic anion transporter 3)ACLY (ATP-citrate synthase)
Beyond the preview
Go deeper on bempedoic acid + obicetrapib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bempedoic acid + obicetrapib.